{
  "source": "PA-Notification-MS.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2025 P 1064-22\nProgram Prior Authorization/Notification\nMedication Multiple Sclerosis - Aubagio® (teriflunomide)*, Avonex® (interferon β-\n1a), Bafiertam™ (monomethyl fumarate), Betaseron® (interferon β-1b),\nCopaxone® (glatiramer acetate)*, dimethyl fumarate, Extavia®\n(interferon β-1b)*, fingolimod, Gilenya® (fingolimod)*, Glatopa™\n(glatiramer acetate), glatiramer acetate, Kesimpta (ofatumumab),\nMayzent (siponimod)®, Plegridy™ (peginterferon β-1a), Ponvory™\n(Ponesimod)*, Rebif® (interferon β-1a)*, Tascenso ODT™\n(fingolimod)*, Tecfidera™ (dimethyl fumarate)*, teriflunomide,\nVumerity™ (diroximel fumarate)*\n*Aubagio (brand), Copaxone (brand), Extavia, Gilenya (brand),\nPonvory, Rebif, Tascenso ODT, Tecfidera (brand), and Vumerity are\nexcluded from coverage for the majority of our benefits.\nMavenclad® (cladribine) coverage is provided according to the product\nspecific Mavenclad Prior Authorization/Notification program\nZeposia® (ozanimod) coverage is provided according to the product\nspecific Zeposia Prior Authorization/Notification program\nP&T Approval Date 5/2011, 5/2012, 11/2012, 07/2013, 08/2013, 5/2014, 10/2014, 10/2015,\n10/2016, 10/2017, 2/2018, 2/2019, 5/2019, 10/2019, 1/2020, 11/2020,\n1/2021, 8/2021, 12/2021, 12/2022, 2/2023, 5/2023, 5/2024, 5/2025\nEffective Date 8/1/2025\n1. Background\nAvonex® and Rebif® (interferon β-1a), Betaseron® and Extavia® (interferon β-1b), Plegridy™\n(peginterferon β-1a), Copaxone® and Glatopa™ (glatiramer acetate), Aubagio®\n(teriflunomide), Mayzent® (siponimod), Tecfidera™ (dimethyl fumarate), Bafiertam™\n(monomethyl fumarate), Kesimpta® (ofatumumab), Ponvory™ (Ponesimod), and Vumerity™\n(diroximel fumarate) are indicated for the treatment of relapsing forms of multiple sclerosis\n(MS), to include clinically isolated syndrome, relapsing-remitting disease, and active\nsecondary progressive disease, in adults.\nGilenya® (fingolimod) is indicated for the treatment of patients with",
    "s\n(MS), to include clinically isolated syndrome, relapsing-remitting disease, and active\nsecondary progressive disease, in adults.\nGilenya® (fingolimod) is indicated for the treatment of patients with relapsing forms of\nmultiple sclerosis, to include clinically isolated syndrome, relapsing-remitting disease, and\nactive secondary progressive disease, in patients 10 years of age and older.6 Tascenso ODT™\n(fingolimod) is indicated for the treatment of relapsing forms of multiple sclerosis, to include\nclinically isolated syndrome, relapsing-remitting disease, and active secondary progressive\ndisease, in pediatric patients 10 years of age and older.16 Due to the risk of a decrease in heart\nrate and/or atrioventricular conduction after the first dose of Gilenya, all patients should be\nobserved for signs and symptoms of bradycardia for at least 6 hours after their first dose.\nFirst-dose monitoring should also be performed when restarting Gilenya after discontinuation\nfor more than 14 days and with dose increases. Novartis, the manufacturer of Gilenya,\nprovides a First-Dose Observation program at no cost to the patient through the GILENYA®\n© 2025 UnitedHealthcare Services, Inc.\n1\nGo Program®. To find a first-dose observation center, visit http://www.gilenya.com/c/ms-\npill/first-day.\n2. Coverage Criteriaa:\nA. Authorization\n1. Aubagio*, Avonex, Bafiertam, Betaseron, Copaxone*, dimethyl fumarate,\nExtavia*, fingolimod, Gilenya*, Glatopa, glatiramer acetate, Kesimpta,\nMayzent, Plegridy, Ponvory*, Rebif*, Tascenso ODT*, Tecfidera*,\nteriflunomide, or Vumerity* will be approved based on the following criterion:\na. Diagnosis of multiple sclerosis (MS)\nAuthorization will be issued for 12 months.\na State mandates may apply. Any federal regulatory requirements and the member specific\nbenefit plan coverage may also impact coverage criteria. Other policies and utilization\nmanagement programs may apply.\n* Aubagio (brand), Copaxone (brand), Extavia, Gilenya (brand), Ponvory, Rebif, Tascens",
    "it plan coverage may also impact coverage criteria. Other policies and utilization\nmanagement programs may apply.\n* Aubagio (brand), Copaxone (brand), Extavia, Gilenya (brand), Ponvory, Rebif, Tascenso ODT,\nTecfidera (brand), and Vumerity are typically excluded from coverage. Coverage reviews may be in\nplace if required by law or the benefit plan.\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-\nauthorization based solely on previous claim/medication history, diagnosis codes (ICD-\n10) and/or claim logic. Use of automated approval and re-approval processes varies by\nprogram and/or therapeutic class.\n• Supply limits and/or Step Therapy may be in place.\n4. References:\n1. Avonex [package insert]. Cambridge, MA: Biogen Inc.; July 2023.\n2. Rebif [package insert]. Rockland, MA: EMD Serono, Inc.; July 2023.\n3. Betaseron [package insert]. Whippany, NJ: Bayer HealthCare Pharmaceuticals Inc.;\nJuly 2023.\n4. Copaxone [package insert]. Parsippany, NJ: Teva Pharmaceuticals USA, Inc.; January\n2025.\n5. Extavia [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation;\nJuly 2023.\n6. Gilenya [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation;\nJune 2024.\n7. Aubagio [package insert]. Cambridge, MA: Genzyme Corporation; December 2022.\n8. Tecfidera [package insert]. Cambridge, MA: Biogen Inc.; March 2024.\n9. Plegridy [package insert]. Cambridge, MA: Biogen Inc.; July 2023.\n10. Glatopa [package insert]. Princeton, NJ: Sandoz Inc.; February 2025.\n11. Mayzent [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation;\nJune 2024.\n12. Vumerity [package insert]. Cambridge, MA: Biogen Inc.; September 2024.\n13. Bafiertam [package insert]. High Point, NC: Banner Life Sciences LLC;\nSeptember2024.\n© 2025 UnitedHealthcare Services, Inc.\n2\n14. Kesimpta [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation;\nJanuary 2024.\n15. Ponvory [package insert]. Titusville, NJ: Janss",
    "r2024.\n© 2025 UnitedHealthcare Services, Inc.\n2\n14. Kesimpta [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation;\nJanuary 2024.\n15. Ponvory [package insert]. Titusville, NJ: Janssen Pharmaceuticals, Inc.; August 2023.\n16. Tascenso ODT [package insert]. San Jose, CA: Handa Neuroscience, LLC; August\n2023.\nProgram Prior Authorization/Notification - MS Agents: Aubagio, Avonex,\nBafiertam, Betaseron, Copaxone, dimethyl fumarate, Extavia,\nfingolimod, Gilenya, Glatopa, Kesimpta, Mayzent, Plegridy, Ponvory,\nRebif, Tascenso ODT, Tecfidera, Vumerity\nChange Control\n5/2014 Annual review. Updated background. Expanded authorization to 60\nmonths, removed reauthorization criteria, and simplified criteria to\nallow coverage for all agents with relapsing forms of MS.\n10/2014 Addition of Plegridy to criteria.\n10/2015 Annual review. Added Glatopa (glatiramer acetate) to criteria.\nRemoved list of medication before the initial authorization. Updated\nbackground and references.\n10/2016 Removed Plegridy from coverage exclusion statements. Updated\nreferences.\n10/2017 Annual review. Updated references.\n2/2018 Revised diagnosis language to match ICD-10 code to maintain\nconsistency across Dx to Rx and manual review. Updated references.\n12/2018 Administrative change to add statement regarding use of automated\nprocesses.\n2/2019 Annual review. Updated references.\n5/2019 Added Mavenclad and Mayzent to criteria.\n10/2019 Added Copaxone to coverage exclusion statement.\n1/2020 Added Vumerity to criteria. Updated background and references.\n11/2020 Added Bafiertam, Kesimpta, and Zeposia to the program. Updated list\nof medications typically excluded from coverage. Changed\nauthorization duration to 12 months. Updated background and\nreferences.\n1/2021 Removed Mavenclad from program as Mavenclad specific program\ndeveloped.\n8/2021 – effective Rebif noted as an excluded drug. Removed notation that Glatopa is an\n1/1/2022 excluded drug. References updated.\n12/2021 – effective Removed Zeposia f",
    "ad specific program\ndeveloped.\n8/2021 – effective Rebif noted as an excluded drug. Removed notation that Glatopa is an\n1/1/2022 excluded drug. References updated.\n12/2021 – effective Removed Zeposia from program as Zeposia specific program\n2/1/2022 developed.\n10/2021 – effective Added Ponvory to program with notation of exclusion.\n5/1/2022\n12/2022 Annual review. Added brand Gilenya and Tascenso ODT to coverage\n© 2025 UnitedHealthcare Services, Inc.\n3\nexclusion statement, background, and criteria. Removed broken\nhyperlink from background, added state mandate, and updated\nreferences.\n2/2023 Updated background with expanded indication for Tascenso ODT per\nFDA label.\n5/2023 Added teriflunomide and noted that brand Aubagio is typically\nexcluded from coverage throughout program.\n5/2024 Annual review with no change to clinical criteria. Updated references.\n5/2025 Annual review with no change to clinical criteria. Updated references.\n© 2025 UnitedHealthcare Services, Inc.\n4"
  ]
}